Brind.
  1. AbbVie is transitioning from legacy drugs to newer blockbusters, acquiring psychedelic drug candidates, and expanding API manufacturing capacity.

AbbVie acquired Gilgamesh Pharmaceuticals' psychedelic drug program, with analysts noting the sector is nearing a tipping point.

2 reports, 1 independent Updated Aug 25
Gone quiet
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

AbbVie acquired Gilgamesh Pharmaceuticals' psychedelic drug program, with analysts noting the sector is nearing a tipping point.

Who's involved

What this event is mainly about
AbbVieGilgamesh Pharmaceuticals

Keep exploring

Part of

AbbVie is transitioning from legacy drugs to newer blockbusters, acquiring psychedelic drug candidates, and expanding API manufacturing capacity. All 2 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • BioPharma DiveAbbVie wagers more than $1B on Gilgamesh’s psychedelic drug This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsl
  • BioPharma DiveIn rumored AbbVie deal, Wall Street sees momentum for psychedelics M&A This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma